Molecule intelOpportunity: LowerEssential

Nevirapine

10 brands · 8 companies · product forms

ATC: J05AG01

Opportunity snapshot

Launch attractiveness
27
Market saturation
21
Price room
4
Regulatory risk
0
10
brands
8
companies
Rs 4,892.11
median price
6
price points
1.18x
price spread
100
confidence %

Who competes here

Top companies by brand count · leader share 20%

Price room

Across observed sources and strengths
CheapestRs 4,144.24
MedianRs 4,892.11
Most expensiveRs 4,898.87
Spread1.18×
Sources: DRAP-official

max/min price ratio 1.18x across 6 trusted points (Rs 4144.24-4898.87). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Brands & products on the market

Sample of 3 live products for Nevirapine — each links to its own medicine page.

Why this score

Launch attractiveness

40% supply-gap(25) + 25% price-variation(4) + 20% low-competition(79) + 15% supply-disruption(0), damped by confidence(100). Higher = more attractive, less crowded opportunity.

Market saturation

8 canonical companies and 10 brands compete (saturation pegged at 30 companies / 150 brands).

Price room

max/min price ratio 1.18x across 6 trusted points (Rs 4144.24-4898.87). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Regulatory risk

No DRAP alerts on this molecule's brands.

Confidence

Full coverage.

Packaged brief for this lower opportunity?

Molecule page + company profiles + price-room analysis are the pilot package for pharma teams.

See packaged reports All 3868 molecules

Molecule intelligence as of 2026-07-30. Brand/company counts from DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.